Danaher Q1 2020 Earnings Report
Key Takeaways
Danaher Corporation reported a 3.0% increase in revenues to $4.3 billion for the first quarter of 2020, with net earnings of $595.1 million, or $0.81 per diluted common share. Non-GAAP adjusted diluted net earnings per common share were $1.05, and core revenue growth was 4.5%. The company also closed its acquisition of the GE Biopharma business, now called Cytiva, on March 31.
Delivered 4.5% core revenue growth.
Closed acquisition of GE Biopharma business (Cytiva) on March 31.
Providing diagnostic testing capabilities and supporting the pursuit of new treatments and vaccines for COVID-19.
Well-positioned to navigate through the uncertain environment due to a strong portfolio, exceptional team, and disciplined execution.
Danaher
Danaher
Forward Guidance
For the second quarter of 2020, Danaher anticipates that non-GAAP core revenue growth including Cytiva will be in the range of approximately flat to down 10%.